Zura Bio reports Q3 2026 results, tibulizumab trials fully enrolled

Zura Bio Limited announced its third quarter 2026 financial results and corporate updates on October 27, 2026. The TibuSHIELD study evaluating tibulizumab in adults with hidradenitis suppurativa completed enrollment in June 2026 with 247 participants, exceeding its target.¹ Topline data remains on track for the fourth quarter of 2026 and will include the primary endpoint of percent change from baseline in total abscess and inflammatory nodule count at Week 16, along with the proportion of participants achieving HiSCR50 or HiSCR75.¹

The TibuSURE study evaluating tibulizumab in adults with early diffuse cutaneous systemic sclerosis completed enrollment in July 2026 with 91 participants, exceeding its target.¹ Topline data remains on track for the first half of 2027 and will include the primary endpoint of change from baseline in modified Rodnan Skin Score (mRSS) at Week 24, as well as measures of lung involvement.¹

A third Phase 2 study, NEXUS-PMR, evaluating tibulizumab in adults with polymyalgia rheumatica, has been cleared by the FDA to proceed under an Investigational New Drug application and remains on track to initiate by year-end 2026.¹

The company said it continues to evaluate potential development approaches for torudokimab (ZB-880) and crebankitug (ZB-168), based on current clinical and translational evidence and an ongoing assessment of the competitive landscape.¹

As of September 30, 2026, Zura had cash and cash equivalents of $187.7 million, which the company expects is sufficient to support planned operations through at least the end of 2028.¹

Research and development expenses were $19.5 million for the quarter, compared to $11.9 million a year earlier,¹ which the company attributed to continued execution of the Phase 2 tibulizumab programs and start-up activities for NEXUS-PMR.¹ Net loss for the quarter was $25.8 million, or $0.20 per share, compared to $18.0 million, or $0.21 per share, in the same period of 2025.¹